NYSE:TGT

Target Corporation (NYSE:TGT) Stock Analysis: Navigating Analyst Ratings and Market Performance

Font: Financial Modeling Prep  • Aug 11, 2026

Market Chart
  • Analyst sentiment for Target Corporation is mixed, with some firms maintaining "hold" ratings while others have upgraded to "buy."
  • Target Corporation stock has shown strong performance, climbing over 50% year-to-date and reaching a new 52-week high of $153.32.
  • The retail giant is undergoing a period of strategic change, including a new Chief Executive Officer, following three years of declining sales and market share loss.

Target Corporation (NYSE:TGT) is a major discount retailer in the United States. The company entered 2026 after three straight years of falling sales and losing market share to its competitors. This period of difficulty also saw the appointment of a new Chief Executive Officer to steer the company forward.

On August 11, 2026, BMO Capital restated its "Market Perform" grade for Target Corporation with a hold action. This rating suggests the analyst expects the stock performance to perform similarly to the overall market. A "hold" advises current shareholders not to sell or buy more shares, as the stock is seen as fairly priced at $152.09.

Other analysts share BMO Capital's cautious view. JPMorgan Chase and Co. maintains a 'neutral' rating, though it raised its price target from $129.00 to $157.00. Similarly, Freedom Capital downgraded Target Corporation from 'strong-buy' to 'hold', and Weiss Ratings confirmed its existing 'hold' rating on the stock.

In contrast, some investment firms are more optimistic. UBS Group issued a 'buy' rating and increased its price target from $144.00 to $166.00. Zacks Research also upgraded the stock from 'hold' to 'strong-buy'. As highlighted by The Motley Fool, TD Cowen also raised its target to $155.00.

This analyst attention follows a strong run for Target Corporation, with its stock climbing over 50% year-to-date. The shares recently set a new 52-week high of $153.32, a significant recovery from its low of $83.44. Investors are now watching for the company's quarterly results, which are scheduled for next week.

Market Overview
MDXH
MDxHealth S.A.
$0.81
74.89%
SURG
SurgePays, Inc.
$0.28
14.36%
VBIO
Valion Bio, Inc.
$0.19
11.59%
NU
Nu Holdings Ltd.
$15.23
9.33%
TSLL
Direxion Daily TSLA Bull 2X ETF
$8.76
1.39%
OTLK
Outlook Therapeutics, Inc.
$0.76
-14.90%
ONDS
Ondas Holdings Inc.
$9.24
3.70%
SPCX
Space Exploration Technologies Corp.
$140.00
-0.91%
INTC
Intel Corp.
$102.50
-1.97%
ONFO
Onfolio Holdings, Inc.
$2.59
12.12%